Symposium Addresses Unique Needs of Young Adults with Rheumatic Diseases PDF Print E-mail
Wednesday, 05 October 2011 07:55

The Arthritis Foundation is sponsoring the 2nd Annual Arthritis in PrimeTime symposium on Saturday, October 22 at the Long Beach Renaissance Hotel in Long Beach. This premier educational and motivational event fosters active and fulfilling lives for young adults (ages 17-45 years old) affected by arthritis, fibromyalgia, lupus, scleroderma, ankylosing spondylitis and other chronic diseases. 



The event's theme is "Making My Work Work–"Work" being broadly defined as college, disability, life transitions, home-making or career. Led by top medical experts and advocates, informational sessions will educate hundreds of participants with chronic diseases about diverse lifestyle issues (including transition from college to the job market, workplace success, social relationships and health insurance issues), as well as research updates and medical treatments for pain management.  

"Most people do not know that arthritis is the #1 cause of work disability in the United States," said Arthritis in PrimeTime chair, Amye Leong, M.B.A. "Arthritis in PrimeTime is a positive, motivating event designed to help over 11 million young people affected with arthritis and other rheumatic diseases lead active, productive lives."  Ms. Leong, who was wheelchair-bound by rheumatoid arthritis, is today the international spokesperson for the United Nations Bone and Joint Decade.

Arthritis in PrimeTime is made possible through the Jane Wyman Trust and Pfizer, and is conducted in partnership with LupusLA, National Fibromyalgia Association, Scleroderma Foundation, Spondylitis Association of America, and Arthritis Introspective. 

The symposium begins at 9 a.m., and ends with an inspirational closing address by Matt Iseman, M.D., renowned comedian and host of Style Network's "Clean House."  Tickets are $25 each or $40 per couple. 

For more information or to register for this event, visit www.arthritisinprimetime.org or contact Jennifer Ziegler at the Arthritis Foundation at 323.954.5760 Ext. 243.

Source: PRNewswire


 
More articles :

» Interleukin-6: A New Therapeutic Target in Scleroderma

Interleukin-6 (IL-6) is a classic pro-inflammatory cytokine critical in mounting an effective immune response. It is secreted by a wide array of cell types; however, its effector cells are more restricted, owing to the fact that very few cells,...

» Caribbean Autoimmune Diseases 2011 Summit Highlights

On Sunday October 2nd 2011, the Caribbean Investor Network hosted its Caribbean Autoimmune Diseases Summit at the Ballroom of the Hilton Hotel and Conference Centre.The Summit delivered an array of excellent presentations ranging from the common...

» A Brief Overview Of Rheumatoid Arthritis

The term arthritis refers to pain, swelling and stiffness of joints. However, joint pain is not a disease but a symptom. It is one of the ways the body tells you that something is wrong. With almost nine million people suffering from Rheumatoid...

» New Promising Therapy Against Systemic Sclerosis

There is a new path to defeat systemic sclerosis, also called because of the hardening of the skin of the patients (from Greek skleros, "hard", and derma, "skin"). This path involves the B-cell of the immune system, so far only considered "innocent...

» Scleroderma and Lupus Health Study Claims No Environmental Link To Disease

The Massachusetts Department of Public Health (DPH) has released the results of an investigation into the occurrence of and lupus, two rare chronic diseases, in South Boston. The investigation found that the prevalence of scleroderma was indeed...

» Recent Study Shows That Stress Can Promote Disease Progression

Stress wreaks havoc on the mind and body. For example, psychological stress is associated with greater risk for depression, heart disease and infectious diseases. But, until now, it has not been clear exactly how stress influences disease and...